Shareholders In Precigen (NASDAQ:PGEN) Should Look Beyond Earnings For The Full Story
Precigen's recent earnings were disappointing, and further analysis reveals worrying underlying numbers. The company's accrual ratio of 1.36 indicates a significant mismatch between profit and free cash flow, with a negative free cash flow of US$74m despite a US$24.4m profit. Additionally, Precigen diluted existing shareholders by issuing new shares, reducing earnings per share, which suggests that the statutory profit may not reflect the true underlying performance of the company.
Precigen, Inc. (PGEN) latest stock news and headlines
This article provides a compilation of recent news and headlines regarding Precigen, Inc. (PGEN), including analysis from Zacks and Simply Wall St. It covers the company's Q3 2026 earnings, stock performance, and analyst expectations. The stock has shown strong trailing total returns, significantly outperforming the S&P 500 over one and three years.
Precigen Q3FY26 Results: Net income $35.8M, revenue up 37% QoQ
Precigen Inc. reported a significant third-quarter net income of $35.8 million and a 37% quarter-over-quarter increase in net product revenue to $72.9 million, driven by the commercial launch of Papcemias. The company achieved profitability ahead of schedule and generated positive operating cash flow, with over 500 patients initiating treatment and broad payer coverage secured. Furthermore, Precigen received an FDA Platform Technology Designation for its AdenoVerse technology, potentially shortening future development timelines, while a key competitor faces an 18-month delay.
Precigen Posts Strong Q3: PAPZIMEOS Net Revenue Rose 37%; Positive Cash Flow Achieved Ahead of Schedule
Precigen Inc. reported strong third-quarter results, driven by a 37% sequential increase in PAPZIMEOS net revenue to $72.9 million, achieving positive cash flow a quarter ahead of schedule. The company posted a net income of $35.8 million, highlighting the commercial success of PAPZIMEOS, an FDA-approved therapy for recurrent respiratory papillomatosis (RRP). Precigen is also expanding its AdenoVerse technology platform, with PRGN-2009 in Phase 2 trials for HPV-related cancers, and is pursuing further growth through redosing studies, pediatric development, and European expansion for PAPZIMEOS.
PGEN Q3 Earnings Call Highlights Launch Momentum and Competition
Precigen's third-quarter 2026 earnings call focused on the accelerating adoption of PAPZIMEOS and strategic efforts to maintain its market lead in recurrent respiratory papillomatosis (RRP). The company reported strong revenue growth for PAPZIMEOS, positive cash generation, and plans for expanding treatment access, while also outlining new indications and pipeline opportunities. Management expressed confidence in future growth and its competitive position despite upcoming market entrants.
Analysts Are Updating Their Precigen, Inc. (NASDAQ:PGEN) Estimates After Its Third-Quarter Results
Precigen, Inc. (NASDAQ:PGEN) shares dropped 36% following its third-quarter results, despite revenues slightly exceeding expectations and earnings per share meeting analyst appraisals. Analysts have maintained their revenue and EPS forecasts for 2027, with no major changes in expectations, and the consensus price target remains at US$13.65. The company is anticipated to experience significant revenue growth, outpacing both its historical performance and the wider industry.
Precigen, Inc. (PGEN) Seasonal Returns Chart - Yahoo Finance
This article from Yahoo Finance provides a seasonal returns chart for Precigen, Inc. (PGEN), detailing average monthly price returns from 2016 to 2026. As of November 6, 2026, PGEN's stock price was 4.4700 USD, having increased by 5.92% at close, though it saw a slight decrease in after-hours trading. The article focuses on historical seasonality data for the company.
Citizens raises Precigen stock price target to $12 on strong sales
Citizens has increased its price target for Precigen Inc. (NASDAQ:PGEN) to $12 from $11, maintaining a Market Outperform rating, due to strong third-quarter sales of PAPZIMEOS which exceeded estimates. The company achieved its first cash flow positive quarter ahead of schedule and analysts anticipate profitability this year. Despite strong financial results, Precigen's stock saw a decline in trading.
Citizens Raises Papzimeos Sales Forecast After Precigen’s Q3 Topline Beat – Sees 142% Upside Potential In PGEN Stock
Citizens has raised its sales forecast for Precigen's RRP drug, Papzimeos, following Precigen's better-than-expected third-quarter revenue of $74.1 million. The firm increased its price target for PGEN stock to $12 from $11, maintaining a 'Market Outperform' rating, which implies a 142% upside. Precigen also achieved its first cash-flow-positive quarter ahead of guidance, reporting $35.8 million in net income.
What Precigen (PGEN) Said on Its Q3 Earnings Call
Precigen (PGEN) reported strong Q3 2026 results, with PAPZIMEOS sales reaching $72.9 million, contributing to a second consecutive profitable quarter and positive cash flow. The company is preparing for competition in the recurrent respiratory papillomatosis (RRP) market, confident in PAPZIMEOS's commercial advantage, clinical results, and established reimbursement. Precigen also outlined plans for redosing studies, pediatric development, international expansion, and further development of its AdenoVerse platform.
Precigen earnings beat by $0.03, revenue topped estimates
Precigen (NASDAQ: PGEN) reported stronger-than-expected third-quarter earnings, beating analyst estimates by $0.03 with an EPS of $0.080. The company's revenue also surpassed consensus estimates, coming in at $74.15M against an expected $69.21M. Despite positive earnings, Precigen's stock is down 30.080% over the last three months, though it has gained 28.950% over the past year.
Precigen Q3 2026 Earnings Call Transcript
Precigen reported strong financial results for Q3 2026, with net product revenue of $72.9 million and a net income of $35.8 million, achieving profitability and positive cash flow ahead of schedule. Their flagship product, Papcemias, for recurrent respiratory papillomatosis (RRP) has seen rapid market adoption with over 500 patients treated. The company plans to expand Papcemias into pediatric populations and global markets, while also leveraging its AdenoVerse platform for future drug development.
Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance
Precigen, Inc. announced strong third quarter 2026 financial results, with PAPZIMEOS net revenue growing 37% quarter-over-quarter to $72.9 million, totaling $151 million since launch. The company achieved positive cash flow a full quarter ahead of guidance, driven by robust PAPZIMEOS uptake and disciplined spending. Net income for the quarter was $35.8 million, and the FDA granted Platform Technology Designation to its AdenoVerse platform, creating opportunities to expedite future therapy development.
Precigen (PGEN) Faces New RRP Rival As Fair Value Debate Comes Into Focus
Precigen (PGEN) is facing increased scrutiny as Inovio's Voceryq received FDA approval for recurrent respiratory papillomatosis, directly competing with Precigen's Papzimeos. This news has led to a significant drop in Precigen's share price, despite a strong long-term return, bringing its fair value and P/S ratio into question. Analysts are divided on the company's valuation, with a consensus target of $13.65 suggesting it's undervalued, contrasting with a high P/S ratio compared to industry averages.
Precigen Bears Take Over Premarket – But Retail Bulls Still See A Buyout Coming
Shares of Precigen (PGEN) plunged 20% in premarket trading following news of Inovio’s new FDA-approved rival treatment, Voceryq, for recurrent respiratory papillomatosis (RRP). Despite the drop, retail investors on Stocktwits remain optimistic about a potential buyout for PGEN, with sentiment reaching an "extremely bullish" high of 94/100, driven by the belief that competition could accelerate a sale. Precigen's Papzimeos, already commercially available, generated $53.1 million in Q2 revenue and has long-term efficacy data supporting its market position, while Q3 projections anticipate significant revenue and earnings growth.
Precigen, Inc. (PGEN) Seasonal returns chart
The article provides a seasonal returns chart for Precigen, Inc. (PGEN), detailing its average monthly price return from 2016 to 2026. It also includes current stock information, recent trading activity, and details about its upcoming Q3 2026 earnings call.
Earnings Preview: Precigen to Report Financial Results Post-market on November 04
Precigen is scheduled to announce its financial results after the market closes on November 4th. Investors will be keen to see if the company's performance has improved, especially given its stock has underperformed the market recently. This report will be a key indicator of its future outlook.
FDA Grants Accelerated Approval to Inovio's DNA Immunotherapy Voceryq; Precigen Shares Plunge 27% After Hours
The FDA has granted accelerated approval to Inovio Pharmaceuticals' DNA-based immunotherapy, Voceryq, for recurrent respiratory papillomatosis. This approval led to a more than 300% surge in Inovio shares after hours, while Precigen, which offers an existing therapy, saw its shares fall 27% due to concerns about its market monopoly. Voceryq is the first plasmid DNA immunotherapy approved in the U.S. and demonstrated significant reduction in surgical procedures in trials, though Inovio must still prove efficacy through additional post-approval trials.
PGEN Q3'26 Earnings: revenue estimate is 71.56M USD
Precigen, Inc. (PGEN) is scheduled to announce its Q3'26 financial results on November 05, with earnings expected at 7:00 AM ET (12:00 PM UTC). Analysts estimate revenue for the quarter to be 71.56 million USD and earnings per share (EPS) at 0.06 USD. The article also provides a table summarizing past revenue and EPS figures, including reported values, estimates, and surprises for previous quarters.
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
Precigen, Inc. (Nasdaq: PGEN) will release its third-quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026. The biopharmaceutical company will host a conference call at 4:30 PM ET on the same day to discuss the results. Participants can access the call via specified North American and international dial-in numbers.
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
Precigen, Inc. (Nasdaq: PGEN) will release its third quarter 2026 financial results and provide business updates on Wednesday, November 4, 2026. The biopharmaceutical company will host a conference call at 4:30 PM ET on that day to discuss the results. This announcement includes cautionary statements regarding forward-looking information.
B. Riley Securities Maintains Precigen(PGEN.US) With Buy Rating, Maintains Target Price $12
B. Riley Securities has reiterated its Buy rating for Precigen (PGEN.US), keeping the target price at $12. This indicates continued confidence in the company's prospects by the investment firm.
Enterprise value to EBITDA forward of Precigen Inc – LS:A2PZG1
This article provides financial data for Precigen Inc (LS:A2PZG1), specifically its enterprise value to EBITDA forward ratio. It notes that the market is currently closed with no trades. The content is primarily a data point within a financial platform, showing the period, value, and change for this metric.
Precigen, Inc. Estimates – NASDAQ:PGEN
This page on TradingView provides financial data and analyst estimates for Precigen, Inc. (NASDAQ:PGEN). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform also visualizes trends over time for both annual and quarterly data.
Precigen, Inc. (PGEN) options chain
This article provides the options chain for Precigen, Inc. (PGEN), listed on NasdaqGS. It displays call and put options with an expiration date of January 19, 2029, including strike prices, last trade dates, last prices, and other trading data. The stock's current price and overnight trading activity are also shown.
Price to earnings forward of Precigen Inc – HAM:I5X
This article provides the "Price to earnings forward" metric for Precigen Inc (HAM:I5X) on the Hamburg Stock Exchange. The data is presented within the TradingView platform, noting that the market is currently closed with no trades. It is a financial snapshot indicating a specific valuation metric for the company.
October 2026's Leading Growth Companies With Strong Insider Ownership
This article identifies top growth companies in the United States with strong insider ownership, highlighting their potential for enhanced performance. It features Hesai Group, Precigen, and Pershing Square, detailing their financial performance, growth forecasts, and insider ownership percentages. The report emphasizes that high insider ownership often aligns management's interests with shareholders, potentially boosting company performance amidst a flat market that has seen a 12% rise over the past year.
Precigen, Inc. (PGEN) stock price, news, quote and history
Precigen, Inc. (PGEN) is a discovery and clinical-stage biopharmaceutical company focused on gene and cell therapies for immuno-oncology, autoimmune, and infectious diseases. The article provides current stock performance, including a -3.13% change at close, and details its key therapeutic platforms like AdenoVerse and UltraCAR-T, along with their respective clinical trials. Financial highlights, analyst ratings, and a company overview are also included.
Precigen Inc Actuals & Estimates (NASDAQ:PGEN)
This article provides an overview of Precigen, Inc. (NASDAQ: PGEN) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals, and estimates for earnings and revenue, noting that PGEN does not pay dividends.
Precigen Inc (PGEN) sentiment score, message volume, participation score and buzz level
This article provides an overview of Precigen Inc (PGEN) stock's sentiment, message volume, and participation ratio on a social trading platform. It indicates whether users are bearish or bullish, the amount of discussion, and the number of unique contributors for the stock. All metrics are currently listed as "N/A Last score N/A" for various timeframes.
High Growth Tech Stocks To Watch In The US October 2026
The U.S. market shows a positive trend with forecasted annual earnings growth of 18%, making high-growth tech stocks an attractive investment. This article highlights three key companies: Precigen (PGEN), Zymeworks (ZYME), and Snowflake (SNOW), detailing their operations, recent achievements, and strong growth projections in revenue and earnings. Each company is leveraging technological advancements like gene therapies, biotherapeutics for cancer, and AI-integrated cloud platforms to drive significant future expansion.
Price to book forward of Precigen Inc – HAM:I5X
This article provides the "Price to book forward" financial metric for Precigen Inc (HAM:I5X) on the Hamburg Stock Exchange. The data is presented for a specific period and includes value, change, and percentage change. The page itself is a financial data overview from TradingView, indicating that there were no trades and the market was closed at the time of viewing.
Why Did Precigen (PGEN) Stock Climb After Its Latest Update?
Precigen (PGEN) stock recently climbed after its AdenoVerse immunotherapy platform received platform technology designation from the US FDA, linking its stock directly to the regulatory pathway of PAPZIMEOS and future candidates. The company's stock has seen significant short-term momentum and long-term growth, with a 90-day return of 52.50% and a year-to-date rise of 99.53%. While some investors see Precigen as 37% undervalued based on a fair value of $13.65, others are wary of its high P/S ratio of 35.7x, which suggests valuation risk if growth assumptions are not met.
$Precigen (PGEN.US)$ DCA up
A Moomoo user, Papacito, shared a post about Precigen (PGEN.US) with the caption "DCA up," indicating an increase in dollar-cost averaging for the stock. The post also includes a general market insight section on "Star Tech Companies" featuring several leading technology stocks and their 20-day percentage change. The user expressed optimism with the phrase "Higher and more to the right 📈".
Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?
Precigen (PGEN) shares rose 6.3% following increased investor confidence regarding sales of its FDA-approved drug, Papzimeos, for recurrent respiratory papillomatosis. The company anticipates significant earnings and revenue growth, with the stock currently holding a Zacks Rank #1 (Strong Buy). However, a lack of recent changes in earnings estimate revisions suggests investors should monitor future developments to gauge sustained momentum.
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
This article compares Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD), two biotech companies heavily reliant on single commercialized drugs, to determine which offers better growth potential. Precigen, with its FDA-approved drug Papzimeos, is positioned as a Strong Buy due to strong early commercial momentum, market exclusivity, and pipeline potential through its AdenoVerse platform. Ironwood, dependent on its GI drug Linzess, shows steady growth but faces vulnerability due to its single-product reliance, making PGEN the preferred investment.
Precigen, Inc. (NASDAQ:PGEN) About To Shift From Loss To Profit
This article analyzes Precigen, Inc.'s financial outlook, focusing on its potential shift from net losses to profitability. It will likely delve into factors such as revenue growth, cost management, and market position that could drive this change. Investors and stakeholders can expect insights into the company's financial health and future prospects.
Precigen Soars As FDA Ruling Ignites Growth Hopes
Precigen (PGEN) shares are soaring after the FDA granted a platform technology designation to its AdenoVerse immunotherapy system, which will expedite drug development and approvals. This ruling, coupled with a "Buy" rating from B. Riley Securities, has boosted investor confidence in Precigen's oncology pipeline and its ability to convert scientific advancements into revenue, particularly with its PAPZIMEOS therapy. Despite strong sales, the company faces challenges with cash burn, debt, and margin pressures, necessitating efficient conversion of demand into sustainable profits.
Total assets of Precigen Inc – HAN:I5X
This article provides financial data for Precigen Inc (HAN:I5X) traded on the Hannover Stock Exchange. It specifically highlights the "Total assets of Precigen Inc" and indicates that the market is currently closed with no trades. The content appears to be a stub or a section from a larger financial data platform.
Learn Why The Bull Case For Precigen (PGEN) Could Change Following FDA Platform Designation
Precigen (PGEN) received FDA platform technology designation for its AdenoVerse immunotherapeutic platform, which could streamline the development of multiple pipeline programs. This designation supports the long-term vision for AdenoVerse as a repeatable product engine, but near-term success still hinges on the commercial performance of PAPZIMEOS and pipeline execution. Analysts project significant revenue and earnings growth for Precigen by 2029, with some already holding optimistic views prior to this FDA announcement.
PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?
This article compares two biotech stocks, Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD), analyzing their growth potential. Both companies heavily rely on a single marketed drug, with Precigen's Papzimeos showing strong early commercial momentum and Ironwood's Linzess also demonstrating healthy demand growth. While Precigen currently holds a "Strong Buy" Zacks Rank due to its promising drug and pipeline, Ironwood faces competition and single-product reliance concerns despite its rising sales.
Return on equity % of Precigen Inc – HAN:I5X
This page from TradingView displays financial data for Precigen Inc (I5X) on the Hannover Stock Exchange, specifically focusing on its Return on Equity (ROE) percentage. The content is part of a broader financial overview for the company, accessible through TradingView's platform.
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?
Moderna (MRNA) and Precigen (PGEN) reached multi-year highs due to positive analyst commentary on their cancer-focused therapies. B. Riley initiated coverage on PGEN with a 'Buy' rating after the FDA approval of Papzimeos, while Bernstein highlighted Moderna's Intismeran as a key validation of its mRNA platform. Both companies are advancing their respective therapies, with Moderna expected to present detailed Phase 3 melanoma data in October.
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies
Precigen (PGEN) has announced that its AdenoVerse immunotherapeutic platform has been granted platform technology designation by the FDA. This designation allows data and review learnings from one product to support future product candidates built on the same backbone, potentially accelerating the development of multiple therapies for various conditions, including HPV-positive cancers. This move is seen as addressing pipeline diversification, providing a clearer regulatory path for AdenoVerse programs by leveraging existing PAPZIMEOS data and manufacturing.
B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target
B. Riley Securities has initiated coverage on Precigen (PGEN) with a Buy rating and a $12 price target, indicating a 55.8% upside from its previous close. The positive outlook is driven by Precigen's strong clinical pipeline, particularly PRGN-2009 for HPV-associated cancers, and its valuable proprietary technology platforms like AdenoVerse immunotherapy and UltraCAR-T. The firm projects significant revenue growth for the company through 2035.
Precigen stock hits 52-week high at 8.05 USD
Precigen Inc.'s stock reached a 52-week high of $8.05, currently trading at $8.10 with a market capitalization of $2.76 billion, reflecting a significant 119.37% increase over the past year. This strong performance follows robust second-quarter results, where the company surpassed analyst expectations due to strong demand for its FDA-approved therapy, PAPZIMEOS, and a "buy" rating initiation from B.Riley with a $12 price target. Despite analysts anticipating sales growth, InvestingPro suggests the stock may be overvalued at its current levels.
Precigen Initiated at Buy by B. Riley Securities
B. Riley Securities has initiated coverage on Precigen (PGEN) with a Buy rating. This indicates a positive outlook from the firm regarding Precigen's stock performance.
Is Precigen (PGEN) Above Fair Value After The FDA Platform Nod?
Precigen (PGEN) has seen significant stock gains recently, raising questions about its valuation relative to its sales and pipeline, especially after receiving FDA platform technology designation for its AdenoVerse immunotherapeutic platform. Despite this, the company's P/S ratio of 32.2x is considerably higher than the biotech industry and peer averages, indicating that its current price may be above its fair value according to various financial models. The article suggests that investors need to weigh whether current sales and product pipeline justify such a steep revenue multiple.
$Precigen (PGEN.US)$ ready for the next leg higher
The article, posted by user Papacito, suggests that Precigen (PGEN.US) is poised for an upward movement in its stock price. It is a brief statement within a financial community platform, with no further analytical details provided in the body of the text.
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos?
Precigen (PGEN) is aiming to expand its growth beyond its successful Papzimeos franchise through its AdenoVerse platform. The company is developing PRGN-2009 for HPV-driven cancers, which recently received FDA platform technology designation, potentially opening doors for future candidates. While Papzimeos continues to drive significant revenue, Precigen hopes the AdenoVerse pipeline, particularly PRGN-2009, will provide long-term growth opportunities and complement its existing commercial success.
